Treats major depressive disorder (MDD). ANDA 205253, held by Zydus Pharms. Trazodone Hydrochloride.
As of Nov 16, 2026, ANDA 205253 (Trazodone Hydrochloride), held by Zydus Pharms, was first approved by FDA on Oct 10, 2017, with 4 approved supplements and 0 published complete response letters.
Trazodone is a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 10, 2017 | Original application | Approved | None posted |
| Trazodone Hydrochloride50MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride100MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride150MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride300MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Jun 24, 2025 | Supplement 24Labeling · Standard review | Approved | None posted |
| Feb 29, 2024 | Supplement 21Manufacturing | Tentative approval | None posted |
| Oct 18, 2022 | Supplement 18Labeling · Standard review | Approved | None posted |
| Oct 30, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 20, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 10, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters